Seattle’s Fred Hutchinson Cancer Research Center is opening a new facility dedicated to testing treatments for people who have tested positive for COVID-19.
The COVID-19 Clinical Research Center, or CCRC is one of the first stand-alone facilities in the country designed for such work, according to Fred Hutch announcement on Monday. Located in the Minor Building on Fred Hutch’s South Lake Union campus, it was funded by philanthropic donations and public/private partnerships.
Scientists and clinicians will partner in the space with study volunteers, health care providers, research institutes, foundations and the biotech/pharmaceutical industry on Phase 1 through 3 clinical trials (observational and interventional) for COVID-19-positive participants.
Two studies are already underway:
- A Phase 3 randomized, double-blind placebo-controlled trial to evaluate the efficacy and safety of remdesivir (GS-5734TM)